Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells.

Sung JJ, Ververis K, Karagiannis TC.

J Photochem Photobiol B. 2014 Feb 5;131:104-12. doi: 10.1016/j.jphotobiol.2014.01.009. Epub 2014 Jan 22.

PMID:
24518645
2.

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.

Heider U, Rademacher J, Lamottke B, Mieth M, Moebs M, von Metzler I, Assaf C, Sezer O.

Eur J Haematol. 2009 Jun;82(6):440-9. doi: 10.1111/j.1600-0609.2009.01239.x. Epub 2009 Feb 10.

PMID:
19220424
3.

SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosis.

Nihal M, Ahmad N, Wood GS.

Cell Cycle. 2014;13(4):632-40. doi: 10.4161/cc.27523. Epub 2013 Dec 16. Erratum in: Cell Cycle. 2015;14(8):1337.

PMID:
24343700
4.

Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.

Shao W, Growney JD, Feng Y, O'Connor G, Pu M, Zhu W, Yao YM, Kwon P, Fawell S, Atadja P.

Int J Cancer. 2010 Nov 1;127(9):2199-208. doi: 10.1002/ijc.25218.

5.

Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma.

Duvic M.

Dermatol Clin. 2015 Oct;33(4):757-64. doi: 10.1016/j.det.2015.05.010. Epub 2015 Aug 29. Review.

6.

Histone deacetylase inhibitors selectively target homology dependent DNA repair defective cells and elevate non-homologous endjoining activity.

Smith S, Fox J, Mejia M, Ruangpradit W, Saberi A, Kim S, Choi Y, Oh S, Wang Y, Choi K, Li L, Hendrickson EA, Takeda S, Muller M, Myung K.

PLoS One. 2014 Jan 23;9(1):e87203. doi: 10.1371/journal.pone.0087203. eCollection 2014.

7.

Impact of histone deacetylase inhibitors SAHA and MS-275 on DNA repair pathways in human mesenchymal stem cells.

Di Bernardo G, Alessio N, Dell'Aversana C, Casale F, Teti D, Cipollaro M, Altucci L, Galderisi U.

J Cell Physiol. 2010 Nov;225(2):537-44. doi: 10.1002/jcp.22236.

PMID:
20458754
8.

BCL11B-Mediated Epigenetic Repression Is a Crucial Target for Histone Deacetylase Inhibitors in Cutaneous T-Cell Lymphoma.

Fu W, Yi S, Qiu L, Sun J, Tu P, Wang Y.

J Invest Dermatol. 2017 Jul;137(7):1523-1532. doi: 10.1016/j.jid.2017.02.980. Epub 2017 Mar 10.

PMID:
28288848
9.

Photosensitization by iodinated DNA minor groove binding ligands: Evaluation of DNA double-strand break induction and repair.

Briggs B, Ververis K, Rodd AL, Foong LJ, Silva FM, Karagiannis TC.

J Photochem Photobiol B. 2011 May 3;103(2):145-52. doi: 10.1016/j.jphotobiol.2011.02.022. Epub 2011 Mar 5.

PMID:
21440453
10.

Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines.

Litvinov IV, Cordeiro B, Fredholm S, Ødum N, Zargham H, Huang Y, Zhou Y, Pehr K, Kupper TS, Woetmann A, Sasseville D.

Cell Cycle. 2014;13(18):2975-82. doi: 10.4161/15384101.2014.947759.

11.

Pharmacological characterization of histone deacetylase inhibitor and tumor cell-growth inhibition properties of new benzofuranone compounds.

Blanquart C, François M, Charrier C, Bertrand P, Gregoire M.

Curr Cancer Drug Targets. 2011 Oct;11(8):919-28.

PMID:
21762083
12.

The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin.

Moyal L, Feldbaum N, Goldfeiz N, Rephaeli A, Nudelman A, Weitman M, Tarasenko N, Gorovitz B, Maron L, Yehezkel S, Amitay-Laish I, Lubin I, Hodak E.

PLoS One. 2016 Jan 11;11(1):e0146115. doi: 10.1371/journal.pone.0146115. eCollection 2016.

13.

Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway.

Yaseen A, Chen S, Hock S, Rosato R, Dent P, Dai Y, Grant S.

Mol Pharmacol. 2012 Dec;82(6):1030-41. doi: 10.1124/mol.112.079624. Epub 2012 Aug 24.

14.

The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.

Tiffon C, Adams J, van der Fits L, Wen S, Townsend P, Ganesan A, Hodges E, Vermeer M, Packham G.

Br J Pharmacol. 2011 Apr;162(7):1590-602. doi: 10.1111/j.1476-5381.2010.01188.x.

15.

The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma.

Hymes KB.

Clin Lymphoma Myeloma Leuk. 2010 Apr;10(2):98-109. doi: 10.3816/CLML.2010.n.014. Review.

PMID:
20371442
16.

Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes.

Gaymes TJ, Shall S, MacPherson LJ, Twine NA, Lea NC, Farzaneh F, Mufti GJ.

Haematologica. 2009 May;94(5):638-46. doi: 10.3324/haematol.2008.001933.

17.

Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives.

Giannini G, Cabri W, Fattorusso C, Rodriquez M.

Future Med Chem. 2012 Jul;4(11):1439-60. doi: 10.4155/fmc.12.80. Review.

PMID:
22857533
18.

Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.

Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C.

J Am Acad Dermatol. 2014 Feb;70(2):223.e1-17; quiz 240-2. doi: 10.1016/j.jaad.2013.08.033. Review.

PMID:
24438970
19.

HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway.

Tsapis M, Lieb M, Manzo F, Shankaranarayanan P, Herbrecht R, Lutz P, Gronemeyer H.

Int J Biochem Cell Biol. 2007;39(7-8):1500-9. Epub 2007 Mar 15.

PMID:
17499001
20.

Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma.

Wozniak MB, Villuendas R, Bischoff JR, Aparicio CB, Martínez Leal JF, de La Cueva P, Rodriguez ME, Herreros B, Martin-Perez D, Longo MI, Herrera M, Piris MA, Ortiz-Romero PL.

Haematologica. 2010 Apr;95(4):613-21. doi: 10.3324/haematol.2009.013870. Epub 2010 Feb 4.

Supplemental Content

Support Center